Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Acronyms ULTRA
- 13 Mar 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 13 Mar 2019 Planned primary completion date changed from 1 Oct 2022 to 1 Jan 2023.
- 13 Mar 2019 Status changed from not yet recruiting to recruiting.